Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study.

Matikainen N, Söderlund S, Björnson E, Pietiläinen K, Hakkarainen A, Lundbom N, Taskinen MR, Borén J

Diabetes, obesity & metabolism4 Sept 2018Cited by 103 (Europe PMC)

PMID30073766PMCIDPMC6585708DOI10.1111/dom.13487PepBankPUB-30073766

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes who got dietary counselling, weight loss at week 16 was similar with liraglutide and placebo.
In plain wordsIn adults with type 2 diabetes, weight loss was similar with liraglutide and with placebo.
Peptide
Liraglutide
Outcome
No significant changeWeight loss at week 16
Study
n = 22
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
1.8 mg once daily · 16 weeksAs given in this study (human).
Source sentences
Summary
Weight loss at Week 16 was similar between the groups: -2.4 kg (-2.5%) in the liraglutide group and -2.1 kg (-2.2%) in the placebo group.
2 context sentences(design, population, supporting numbers)
Summary · context
The effect of liraglutide was investigated in 22 patients with adequately controlled type 2 diabetes.
Summary · context
Patients were randomly allocated, in a single-blind fashion, to either liraglutide 1.8 mg or placebo once daily for 16 weeks.
Report a problemFND-3007376601
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, HbA1c improved by 6.4 mmol/mol (0.6%) in the liraglutide group.
In plain wordsIn adults with type 2 diabetes, HbA1c improved in the liraglutide group.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change
Study
n = 22
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg once daily · 16 weeksAs given in this study (human).
Source sentences
Summary
HBA1c improved by 6.4 mmol/mol (0.6%) in the liraglutide group (P = 0.005).
2 context sentences(design, population, supporting numbers)
Summary · context
The effect of liraglutide was investigated in 22 patients with adequately controlled type 2 diabetes.
Summary · context
Patients were randomly allocated, in a single-blind fashion, to either liraglutide 1.8 mg or placebo once daily for 16 weeks.
Report a problemFND-3007376602
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, liver fat fell in both groups, by 31% with liraglutide and by 18% with placebo.
In plain wordsIn adults with type 2 diabetes, liver fat fell in both the liraglutide and placebo groups.
Peptide
Liraglutide
Outcome
DecreaseLiver fat
Study
n = 22
Comparator
Placebo
Outcome group
Liver fat and liver function · Liver
Studied dose
1.8 mg once daily · 16 weeksAs given in this study (human).
Source sentences
Summary
Liver fat decreased in both groups, by 31% in the liraglutide group and by 18% in the placebo group
2 context sentences(design, population, supporting numbers)
Summary · context
The effect of liraglutide was investigated in 22 patients with adequately controlled type 2 diabetes.
Summary · context
Patients were randomly allocated, in a single-blind fashion, to either liraglutide 1.8 mg or placebo once daily for 16 weeks.
Report a problemFND-3007376603
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, liraglutide caused no significant change in the rate of hepatic de novo lipogenesis.
In plain wordsIn adults with type 2 diabetes, liraglutide did not significantly change how fast the liver makes new fat.
Peptide
Liraglutide
Outcome
No significant changeHepatic de novo lipogenesis
Study
n = 22
Outcome group
Liver fat and liver function · Liver
Studied dose
1.8 mg once daily · 16 weeksAs given in this study (human).
Source sentences
Summary
but there were no significant changes in the rate of hepatic de novo lipogenesis or β-hydroxybutyrate levels, a marker of fat oxidation.
2 context sentences(design, population, supporting numbers)
Summary · context
The effect of liraglutide was investigated in 22 patients with adequately controlled type 2 diabetes.
Summary · context
Patients were randomly allocated, in a single-blind fashion, to either liraglutide 1.8 mg or placebo once daily for 16 weeks.
Report a problemFND-3007376604
05HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, liraglutide caused no significant change in beta-hydroxybutyrate, a marker of fat oxidation.
In plain wordsIn adults with type 2 diabetes, liraglutide did not significantly change a marker of fat burning.
Peptide
Liraglutide
Outcome
No significant changeBeta-hydroxybutyrate level
Study
n = 22
Outcome group
Liver fat and liver function · Metabolic and weight
Studied dose
1.8 mg once daily · 16 weeksAs given in this study (human).
Source sentences
Summary
but there were no significant changes in the rate of hepatic de novo lipogenesis or β-hydroxybutyrate levels, a marker of fat oxidation.
2 context sentences(design, population, supporting numbers)
Summary · context
The effect of liraglutide was investigated in 22 patients with adequately controlled type 2 diabetes.
Summary · context
Patients were randomly allocated, in a single-blind fashion, to either liraglutide 1.8 mg or placebo once daily for 16 weeks.
Report a problemFND-3007376605
06HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, postprandial plasma triglycerides decreased significantly after liraglutide and not in the placebo group.
In plain wordsIn adults with type 2 diabetes, blood fats after a meal fell with liraglutide but not with placebo.
Peptide
Liraglutide
Outcome
DecreasePostprandial plasma triglycerides
Study
n = 22
Comparator
Placebo
Outcome group
Lipids · Metabolic and weight
Studied dose
1.8 mg once daily · 16 weeksAs given in this study (human).
Source sentences
Summary
We observed significant postprandial decreases in triglycerides only in plasma, chylomicrons and VLDL, and remnant particle cholesterol after treatment in the liraglutide group.
2 context sentences(design, population, supporting numbers)
Summary · context
The effect of liraglutide was investigated in 22 patients with adequately controlled type 2 diabetes.
Summary · context
Patients were randomly allocated, in a single-blind fashion, to either liraglutide 1.8 mg or placebo once daily for 16 weeks.
Report a problemFND-3007376606
07HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, postprandial chylomicron triglycerides decreased significantly after liraglutide and not in the placebo group.
In plain wordsIn adults with type 2 diabetes, fat in chylomicron particles after a meal fell with liraglutide but not with placebo.
Peptide
Liraglutide
Outcome
DecreasePostprandial chylomicron triglycerides
Study
n = 22
Comparator
Placebo
Outcome group
Lipids · Metabolic and weight
Studied dose
1.8 mg once daily · 16 weeksAs given in this study (human).
Source sentences
Summary
We observed significant postprandial decreases in triglycerides only in plasma, chylomicrons and VLDL, and remnant particle cholesterol after treatment in the liraglutide group.
2 context sentences(design, population, supporting numbers)
Summary · context
The effect of liraglutide was investigated in 22 patients with adequately controlled type 2 diabetes.
Summary · context
Patients were randomly allocated, in a single-blind fashion, to either liraglutide 1.8 mg or placebo once daily for 16 weeks.
Report a problemFND-3007376607
08HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, postprandial VLDL triglycerides decreased significantly after liraglutide and not in the placebo group.
In plain wordsIn adults with type 2 diabetes, fat in VLDL particles after a meal fell with liraglutide but not with placebo.
Peptide
Liraglutide
Outcome
DecreasePostprandial VLDL triglycerides
Study
n = 22
Comparator
Placebo
Outcome group
Lipids · Metabolic and weight
Studied dose
1.8 mg once daily · 16 weeksAs given in this study (human).
Source sentences
Summary
We observed significant postprandial decreases in triglycerides only in plasma, chylomicrons and VLDL, and remnant particle cholesterol after treatment in the liraglutide group.
2 context sentences(design, population, supporting numbers)
Summary · context
The effect of liraglutide was investigated in 22 patients with adequately controlled type 2 diabetes.
Summary · context
Patients were randomly allocated, in a single-blind fashion, to either liraglutide 1.8 mg or placebo once daily for 16 weeks.
Report a problemFND-3007376608
09HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, postprandial remnant particle cholesterol decreased significantly after liraglutide and not in the placebo group.
In plain wordsIn adults with type 2 diabetes, remnant cholesterol after a meal fell with liraglutide but not with placebo.
Peptide
Liraglutide
Outcome
DecreasePostprandial remnant particle cholesterol
Study
n = 22
Comparator
Placebo
Outcome group
Lipids · Metabolic and weight
Studied dose
1.8 mg once daily · 16 weeksAs given in this study (human).
Source sentences
Summary
We observed significant postprandial decreases in triglycerides only in plasma, chylomicrons and VLDL, and remnant particle cholesterol after treatment in the liraglutide group.
2 context sentences(design, population, supporting numbers)
Summary · context
The effect of liraglutide was investigated in 22 patients with adequately controlled type 2 diabetes.
Summary · context
Patients were randomly allocated, in a single-blind fashion, to either liraglutide 1.8 mg or placebo once daily for 16 weeks.
Report a problemFND-3007376609
10HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, fasting apoCIII concentrations decreased after liraglutide intervention.
In plain wordsIn adults with type 2 diabetes, fasting levels of apoCIII, a fat-regulating protein, fell after liraglutide.
Peptide
Liraglutide
Outcome
DecreaseFasting apoCIII concentration
Study
n = 22
Outcome group
Lipids · Metabolic and weight
Studied dose
1.8 mg once daily · 16 weeksAs given in this study (human).
Source sentences
Summary
Fasting and postprandial apoCIII concentrations decreased after liraglutide intervention and these changes were closely related to reduced glycaemia.
2 context sentences(design, population, supporting numbers)
Summary · context
The effect of liraglutide was investigated in 22 patients with adequately controlled type 2 diabetes.
Summary · context
Patients were randomly allocated, in a single-blind fashion, to either liraglutide 1.8 mg or placebo once daily for 16 weeks.
Report a problemFND-3007376610
11HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, postprandial apoCIII concentrations decreased after liraglutide intervention.
In plain wordsIn adults with type 2 diabetes, apoCIII levels after a meal fell after liraglutide.
Peptide
Liraglutide
Outcome
DecreasePostprandial apoCIII concentration
Study
n = 22
Outcome group
Lipids · Metabolic and weight
Studied dose
1.8 mg once daily · 16 weeksAs given in this study (human).
Source sentences
Summary
Fasting and postprandial apoCIII concentrations decreased after liraglutide intervention and these changes were closely related to reduced glycaemia.
2 context sentences(design, population, supporting numbers)
Summary · context
The effect of liraglutide was investigated in 22 patients with adequately controlled type 2 diabetes.
Summary · context
Patients were randomly allocated, in a single-blind fashion, to either liraglutide 1.8 mg or placebo once daily for 16 weeks.
Report a problemFND-3007376611
12HumanRandomized controlled trialMechanism
In adults with type 2 diabetes on liraglutide, about half of the changes in postprandial lipids were explained by reductions in apoCIII, and less than 10% by weight, glycaemic control, liver fat or insulin responses.
In plain wordsIn adults with type 2 diabetes on liraglutide, about half of the change in after-meal blood fats was explained by lower apoCIII.
Peptide
Liraglutide
Outcome
Not applicableShare of postprandial lipid change explained by apoCIII
Study
n = 22
Outcome group
Lipids · Metabolic and weight
Studied dose
1.8 mg once daily · 16 weeksAs given in this study (human).
Source sentences
Summary
In relative importance analysis, approximately half of the changes in postprandial lipids were explained by reductions in apoCIII concentrations, whereas less than 10% of the variation in postprandial lipids was explained by reductions in weight, glycaemic control, liver fat or postprandial insulin responses.
2 context sentences(design, population, supporting numbers)
Summary · context
The effect of liraglutide was investigated in 22 patients with adequately controlled type 2 diabetes.
Summary · context
Patients were randomly allocated, in a single-blind fashion, to either liraglutide 1.8 mg or placebo once daily for 16 weeks.
Report a problemFND-3007376612

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4Results postedNCT02765399

The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis

Helsinki University Central Hospitaln = 231 Feb 2015 to 28 Feb 2019

Type 2 Diabetes

Trial page ClinicalTrials.govUpdated 12 Apr 2022

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.